Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
8.03
-0.01 (-0.12%)
At close: May 4, 2026, 4:00 PM EDT
8.08
+0.05 (0.62%)
Pre-market: May 5, 2026, 6:45 AM EDT
Company Description
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally.
The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine.
The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax, Inc.
| Country | United States |
| Founded | 1987 |
| IPO Date | Dec 5, 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 749 |
| CEO | John Jacobs |
Contact Details
Address: 21 Firstfield Road Gaithersburg, Maryland 20878 United States | |
| Phone | 240 268 2000 |
| Website | novavax.com |
Stock Details
| Ticker Symbol | NVAX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001000694 |
| CUSIP Number | 670002401 |
| ISIN Number | US6700024010 |
| Employer ID | 22-2816046 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| John Charles Jacobs M.B.A. | President, Chief Executive Officer and Director |
| James Patrick Kelly C.F.A. | Executive Vice President, Chief Financial Officer and Treasurer |
| Elaine O'Hara | Executive Vice President and Chief Strategy Officer |
| Richard P. Crowley | Executive Vice President and Chief Operating Officer |
| Luis Sanay C.F.A. | Vice President of Investor Relations |
| Troy Morgan Esq., J.D. | Senior Vice President, Deputy General Counsel and Chief Compliance Officer |
| Erika S. Trahan | Associate Director of Investor and Public Relations |
| Ian J. Watkins | Executive Vice President and Chief Human Resources Officer |
| Silvia Taylor M.B.A. | Executive Vice President, Chief Corporate Affairs Officer and Head of Novavax Sweden |
| Dr. Robert Walker M.D. | Executive Vice President and Head of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2026 | SCHEDULE 13G | Filing |
| Apr 27, 2026 | SCHEDULE 13G/A | Filing |
| Apr 27, 2026 | ARS | Filing |
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2026 | SCHEDULE 13D/A | Filing |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 11, 2026 | SCHEDULE 13G | Filing |